Short-term results of the efficacy of percutaneous tibial nerve stimulation on urinary symptoms and its financial cost

Zehra Kurdoğlu, Danielle Carr, Jihad Harmouche, Serdar Ünlü, Gokhan Kilic

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: Overactive bladder (OAB) affects 16.9% of women in the United States. Percutaneous tibial nerve stimulation (PTNS) is a third-line treatment for patients who are refractory to behavioral and pharmacologic therapies. We aimed to evaluate the effects of PTNS on urinary symptoms in patients diagnosed as having refractory OAB and investigate the cost of medications and clinical visits before and after PTNS treatment. Material and Methods: We reviewed 60 women with refractory OAB treated with PTNS. Episodes of urinary frequency, leakage, urgency, and nocturia; number of follow-up visits; and medications were recorded. The mean quarterly drug, physician, nurse, and provider costs were calculated. The episodes of urinary symptoms, numbers of follow-up visits, and costs of medications and visits before and after PTNS were compared. Results: Of the 60 patients with refractory OAB, 24 patients who completed 12 weekly sessions of initial PTNS were evaluated. The number of urinary symptoms and follow-up visits significantly decreased after PTNS (p<0.05). The average quarterly medication cost decreased from $656.36±292.45 to $375.51±331.79 after PTNS (p=0.001). After PTNS, quarterly physician and nurse visit costs decreased from $81.73±70.39 to $25.89±54.40 and from $55.23±38.32 to $15.53±19.58, respectively (p<0.05). The quarterly total provider cost was similar before and after PTNS. Conclusion: PTNS treatment significantly improved urinary symptoms of patients with refractory OAB and reduced the costs of medications and physician and nurse visits.

Original languageEnglish (US)
Pages (from-to)7-10
Number of pages4
JournalJournal of the Turkish German Gynecology Association
Volume19
Issue number1
DOIs
StatePublished - Mar 1 2018

Fingerprint

Tibial Nerve
Costs and Cost Analysis
Overactive Urinary Bladder
Nurses
Physicians
Nocturia
Therapeutics

Keywords

  • Costs and cost analysis
  • Lower urinary tract symptoms
  • Office visits
  • Overactive
  • Tibial nerve
  • Transcutaneous electric nerve stimulation
  • Urinary bladder

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Short-term results of the efficacy of percutaneous tibial nerve stimulation on urinary symptoms and its financial cost. / Kurdoğlu, Zehra; Carr, Danielle; Harmouche, Jihad; Ünlü, Serdar; Kilic, Gokhan.

In: Journal of the Turkish German Gynecology Association, Vol. 19, No. 1, 01.03.2018, p. 7-10.

Research output: Contribution to journalArticle

@article{a281c9223dd641e684f8d02f6dd2d0ac,
title = "Short-term results of the efficacy of percutaneous tibial nerve stimulation on urinary symptoms and its financial cost",
abstract = "Objective: Overactive bladder (OAB) affects 16.9{\%} of women in the United States. Percutaneous tibial nerve stimulation (PTNS) is a third-line treatment for patients who are refractory to behavioral and pharmacologic therapies. We aimed to evaluate the effects of PTNS on urinary symptoms in patients diagnosed as having refractory OAB and investigate the cost of medications and clinical visits before and after PTNS treatment. Material and Methods: We reviewed 60 women with refractory OAB treated with PTNS. Episodes of urinary frequency, leakage, urgency, and nocturia; number of follow-up visits; and medications were recorded. The mean quarterly drug, physician, nurse, and provider costs were calculated. The episodes of urinary symptoms, numbers of follow-up visits, and costs of medications and visits before and after PTNS were compared. Results: Of the 60 patients with refractory OAB, 24 patients who completed 12 weekly sessions of initial PTNS were evaluated. The number of urinary symptoms and follow-up visits significantly decreased after PTNS (p<0.05). The average quarterly medication cost decreased from $656.36±292.45 to $375.51±331.79 after PTNS (p=0.001). After PTNS, quarterly physician and nurse visit costs decreased from $81.73±70.39 to $25.89±54.40 and from $55.23±38.32 to $15.53±19.58, respectively (p<0.05). The quarterly total provider cost was similar before and after PTNS. Conclusion: PTNS treatment significantly improved urinary symptoms of patients with refractory OAB and reduced the costs of medications and physician and nurse visits.",
keywords = "Costs and cost analysis, Lower urinary tract symptoms, Office visits, Overactive, Tibial nerve, Transcutaneous electric nerve stimulation, Urinary bladder",
author = "Zehra Kurdoğlu and Danielle Carr and Jihad Harmouche and Serdar {\"U}nl{\"u} and Gokhan Kilic",
year = "2018",
month = "3",
day = "1",
doi = "10.4274/jtgga.2017.0115",
language = "English (US)",
volume = "19",
pages = "7--10",
journal = "Journal of the Turkish German Gynecology Association",
issn = "1309-0399",
publisher = "Aves",
number = "1",

}

TY - JOUR

T1 - Short-term results of the efficacy of percutaneous tibial nerve stimulation on urinary symptoms and its financial cost

AU - Kurdoğlu, Zehra

AU - Carr, Danielle

AU - Harmouche, Jihad

AU - Ünlü, Serdar

AU - Kilic, Gokhan

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Objective: Overactive bladder (OAB) affects 16.9% of women in the United States. Percutaneous tibial nerve stimulation (PTNS) is a third-line treatment for patients who are refractory to behavioral and pharmacologic therapies. We aimed to evaluate the effects of PTNS on urinary symptoms in patients diagnosed as having refractory OAB and investigate the cost of medications and clinical visits before and after PTNS treatment. Material and Methods: We reviewed 60 women with refractory OAB treated with PTNS. Episodes of urinary frequency, leakage, urgency, and nocturia; number of follow-up visits; and medications were recorded. The mean quarterly drug, physician, nurse, and provider costs were calculated. The episodes of urinary symptoms, numbers of follow-up visits, and costs of medications and visits before and after PTNS were compared. Results: Of the 60 patients with refractory OAB, 24 patients who completed 12 weekly sessions of initial PTNS were evaluated. The number of urinary symptoms and follow-up visits significantly decreased after PTNS (p<0.05). The average quarterly medication cost decreased from $656.36±292.45 to $375.51±331.79 after PTNS (p=0.001). After PTNS, quarterly physician and nurse visit costs decreased from $81.73±70.39 to $25.89±54.40 and from $55.23±38.32 to $15.53±19.58, respectively (p<0.05). The quarterly total provider cost was similar before and after PTNS. Conclusion: PTNS treatment significantly improved urinary symptoms of patients with refractory OAB and reduced the costs of medications and physician and nurse visits.

AB - Objective: Overactive bladder (OAB) affects 16.9% of women in the United States. Percutaneous tibial nerve stimulation (PTNS) is a third-line treatment for patients who are refractory to behavioral and pharmacologic therapies. We aimed to evaluate the effects of PTNS on urinary symptoms in patients diagnosed as having refractory OAB and investigate the cost of medications and clinical visits before and after PTNS treatment. Material and Methods: We reviewed 60 women with refractory OAB treated with PTNS. Episodes of urinary frequency, leakage, urgency, and nocturia; number of follow-up visits; and medications were recorded. The mean quarterly drug, physician, nurse, and provider costs were calculated. The episodes of urinary symptoms, numbers of follow-up visits, and costs of medications and visits before and after PTNS were compared. Results: Of the 60 patients with refractory OAB, 24 patients who completed 12 weekly sessions of initial PTNS were evaluated. The number of urinary symptoms and follow-up visits significantly decreased after PTNS (p<0.05). The average quarterly medication cost decreased from $656.36±292.45 to $375.51±331.79 after PTNS (p=0.001). After PTNS, quarterly physician and nurse visit costs decreased from $81.73±70.39 to $25.89±54.40 and from $55.23±38.32 to $15.53±19.58, respectively (p<0.05). The quarterly total provider cost was similar before and after PTNS. Conclusion: PTNS treatment significantly improved urinary symptoms of patients with refractory OAB and reduced the costs of medications and physician and nurse visits.

KW - Costs and cost analysis

KW - Lower urinary tract symptoms

KW - Office visits

KW - Overactive

KW - Tibial nerve

KW - Transcutaneous electric nerve stimulation

KW - Urinary bladder

UR - http://www.scopus.com/inward/record.url?scp=85045188476&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045188476&partnerID=8YFLogxK

U2 - 10.4274/jtgga.2017.0115

DO - 10.4274/jtgga.2017.0115

M3 - Article

AN - SCOPUS:85045188476

VL - 19

SP - 7

EP - 10

JO - Journal of the Turkish German Gynecology Association

JF - Journal of the Turkish German Gynecology Association

SN - 1309-0399

IS - 1

ER -